{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:51:59Z","timestamp":1793238719848,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","award":["CRI-CLIP"],"award-info":[{"award-number":["CRI-CLIP"]}],"id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CD137 (4-1BB; TNFSR9) is an activation-induced surface receptor that through costimulation effects provide antigen-primed T cells with augmented survival, proliferation and effector functions as well as metabolic advantages. These immunobiological mechanisms are being utilised for cancer immunotherapy with agonist CD137-binding and crosslinking-inducing agents that elicit CD137 intracellular signaling. In this study, side-by-side comparisons show that provision of CD137 costimulation in-cis with regard to the TCR-CD3-ligating cell is superior to that provided in-trans in terms of T cell activation, proliferation, survival, cytokine secretion and mitochondrial fitness in mouse and human. Cis ligation of CD137 relative to the TCR-CD3 complex results in more intense canonical and non-canonical NF-\u03baB signaling and provides a more robust induction of cell cycle and DNA damage repair gene expression programs. Here we report that the superiority of cis versus trans CD137-costimulation is readily observed in vivo and is relevant for understanding the immunotherapeutic effects of CAR T cells and CD137 agonistic therapies currently undergoing clinical trials, which may provide costimulation either in cis or in trans.<\/jats:p>","DOI":"10.1038\/s41467-021-27613-w","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T11:05:44Z","timestamp":1639566344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1433-1711","authenticated-orcid":false,"given":"Itziar","family":"Otano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantza","family":"Azpilikueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8936-190X","authenticated-orcid":false,"given":"Javier","family":"Glez-Vaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5969-9181","authenticated-orcid":false,"given":"Maite","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Medina-Echeverz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Cort\u00e9s-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8720-0205","authenticated-orcid":false,"given":"Carlos","family":"Ortiz-de-Solorzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ellmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Fritzell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Hernandez-Hoyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Hase","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9920-2144","authenticated-orcid":false,"given":"Mar\u00eda Carmen","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elixabet","family":"Bola\u00f1os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doina","family":"Cuculescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ja\u00faregui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sanchez-Gregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-0836","authenticated-orcid":false,"given":"I\u00f1aki","family":"Etxeberria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda E.","family":"Rodriguez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel F.","family":"Sanmamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Teijeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7410-1865","authenticated-orcid":false,"given":"Pedro","family":"Berraondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"27613_CR1","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1073\/pnas.86.6.1963","volume":"86","author":"BS Kwon","year":"1989","unstructured":"Kwon, B. S. & Weissman, S. M. cDNA sequences of two inducible T-cell genes. Proc. Natl Acad. Sci. USA 86, 1963\u20131967 (1989).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"27613_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1006\/smim.1998.0157","volume":"10","author":"DS Vinay","year":"1998","unstructured":"Vinay, D. S. & Kwon, B. S. Role of 4-1BB in immune responses. Semin. Immunol. 10, 481\u2013489 (1998).","journal-title":"Semin. Immunol."},{"key":"27613_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1600-065X.2009.00765.x","volume":"229","author":"C Wang","year":"2009","unstructured":"Wang, C., Lin, G. H. Y., McPherson, A. J. & Watts, T. H. Immune regulation by 4-1BB and 4-1BBL: Complexities and challenges. Immunological Rev. 229, 192\u2013215 (2009).","journal-title":"Immunological Rev."},{"key":"27613_CR4","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/(SICI)1521-4141(199803)28:03<1116::AID-IMMU1116>3.0.CO;2-A","volume":"28","author":"I Melero","year":"1998","unstructured":"Melero, I. et al. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: Synergy with the CD28 co-stimulatory pathway. Eur. J. Immunol. 28, 1116\u20131121 (1998).","journal-title":"Eur. J. Immunol."},{"key":"27613_CR5","doi-asserted-by":"crossref","unstructured":"Etxeberria, I., Glez-Vaz, J., Teijeira, \u00c1. & Melero, I. New emerging targets in cancer immunotherapy: CD137\/4-1BB costimulatory axis. ESMO open 4 e000733 (2020).","DOI":"10.1136\/esmoopen-2020-000733"},{"key":"27613_CR6","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.4049\/jimmunol.168.11.5483","volume":"168","author":"BS Kwon","year":"2002","unstructured":"Kwon, B. S. et al. Immune Responses in 4-1BB (CD137)-Deficient Mice. J. Immunol. 168, 5483\u20135490 (2002).","journal-title":"J. Immunol."},{"key":"27613_CR7","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.4049\/jimmunol.163.9.4833","volume":"163","author":"MA DeBenedette","year":"1999","unstructured":"DeBenedette, M. A. et al. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus - PubMed. J. Immunol. 163, 4833\u20134841 (1999).","journal-title":"J. Immunol."},{"key":"27613_CR8","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1182\/blood.2019000644","volume":"134","author":"I Somekh","year":"2019","unstructured":"Somekh, I. et al. CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis. Blood 134, 1510\u20131516 (2019).","journal-title":"Blood"},{"key":"27613_CR9","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jaci.2019.03.002","volume":"144","author":"MF Alosaimi","year":"2019","unstructured":"Alosaimi, M. F. et al. Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency. J. Allergy Clin. Immunol. 144, 574\u2013583.e5 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"27613_CR10","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1084\/jem.20190678","volume":"216","author":"R Rodriguez","year":"2019","unstructured":"Rodriguez, R. et al. Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells. J. Exp. Med. 216, 2800\u20132818 (2019).","journal-title":"J. Exp. Med."},{"key":"27613_CR11","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1084\/jem.187.11.1849","volume":"187","author":"K Saoulli","year":"1998","unstructured":"Saoulli, K. et al. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4- 1BB ligand. J. Exp. Med. 187, 1849\u20131862 (1998).","journal-title":"J. Exp. Med."},{"key":"27613_CR12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1006\/bbrc.1997.8016","volume":"242","author":"IK Jang","year":"1998","unstructured":"Jang, I. K., Lee, Z. H., Kim, Y. J., Kim, S. H. & Kwon, B. S. Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-\u03baB. Biochemical Biophysical Res. Commun. 242, 613\u2013620 (1998).","journal-title":"Biochemical Biophysical Res. Commun."},{"key":"27613_CR13","doi-asserted-by":"crossref","unstructured":"Zapata, J. M. et al. CD137 (4-1BB) signalosome: Complexity is a matter of TRAFs. Front. Immunol. 9, 2618 (2018).","DOI":"10.3389\/fimmu.2018.02618"},{"key":"27613_CR14","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.4049\/jimmunol.165.11.6193","volume":"165","author":"JL Cannons","year":"2000","unstructured":"Cannons, J. L., Choi, Y. & Watts, T. H. Role of TNF Receptor-Associated Factor 2 and p38 Mitogen-Activated Protein Kinase Activation During 4-1BB-Dependent Immune Response. J. Immunol. 165, 6193\u20136204 (2000).","journal-title":"J. Immunol."},{"key":"27613_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nm0697-682","volume":"3","author":"I Melero","year":"1997","unstructured":"Melero, I. et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3, 682\u2013685 (1997).","journal-title":"Nat. Med."},{"key":"27613_CR16","doi-asserted-by":"publisher","first-page":"6895","DOI":"10.1158\/1078-0432.CCR-08-0285","volume":"14","author":"O Murillo","year":"2008","unstructured":"Murillo, O. et al. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin. Cancer Res. 14, 6895\u20136906 (2008).","journal-title":"Clin. Cancer Res."},{"key":"27613_CR17","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/ajh.25757","volume":"95","author":"J Timmerman","year":"2020","unstructured":"Timmerman, J. et al. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. Am. J. Hematol. 95, 510\u2013520 (2020).","journal-title":"Am. J. Hematol."},{"key":"27613_CR18","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1158\/1078-0432.CCR-16-1272","volume":"23","author":"NH Segal","year":"2017","unstructured":"Segal, N. H. et al. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. Clin. Cancer Res. 23, 1929\u20131936 (2017).","journal-title":"Clin. Cancer Res."},{"key":"27613_CR19","unstructured":"Claus, C. et al. Tumor-Targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-The-shelf therapy. Sci. Trans. Med. 11, eaav5989 (2019)."},{"key":"27613_CR20","doi-asserted-by":"publisher","unstructured":"Kamata-Sakurai, M. et al. Antibody to CD137 activated by extracellular adenosine triphosphate is tumor selective and broadly effective in vivo without systemic immune activation. Cancer Dis. CD-20-0328 (2020) https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0328.","DOI":"10.1158\/2159-8290.CD-20-0328"},{"key":"27613_CR21","doi-asserted-by":"crossref","unstructured":"Compte, M. et al. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity. Nat. Commun. 9, 4809 (2018).","DOI":"10.1038\/s41467-018-07195-w"},{"key":"27613_CR22","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1158\/1078-0432.CCR-18-3654","volume":"25","author":"MJ Hinner","year":"2019","unstructured":"Hinner, M. J. et al. Tumor-localized costimulatory T-cell engagement by the 4-1BB\/HER2 bispecific antibody-anticalin fusion PRS-343. Clin. Cancer Res. 25, 5878\u20135889 (2019).","journal-title":"Clin. Cancer Res."},{"key":"27613_CR23","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-19-2958","volume":"26","author":"MA Lakins","year":"2020","unstructured":"Lakins, M. A. et al. FS222, a CD137\/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 26, 4154\u20134167 (2020).","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"27613_CR24","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0813101106","volume":"106","author":"C Carpenito","year":"2009","unstructured":"Carpenito, C. et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 106, 3360\u20133365 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"27613_CR25","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"27613_CR26","doi-asserted-by":"crossref","unstructured":"Liu, Y. & Janeway, C. A. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc. Natl. Acad. Sci. USA. 89, 3845\u20139 (1992).","DOI":"10.1073\/pnas.89.9.3845"},{"key":"27613_CR27","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nri3307","volume":"12","author":"SM Kaech","year":"2012","unstructured":"Kaech, S. M. & Cui, W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat. Rev. Immunol. 12, 749\u2013761 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"27613_CR28","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1158\/2326-6066.CIR-17-0767","volume":"6","author":"A Teijeira","year":"2018","unstructured":"Teijeira, A. et al. Mitochondrial morphological and functional reprogramming following CD137 (4-1BB) Costimulation. Cancer Immunol. Res. 6, 798\u2013811 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"27613_CR29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar, O. U. et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity 44, 380\u2013390 (2016).","journal-title":"Immunity"},{"key":"27613_CR30","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1084\/jem.20171068","volume":"215","author":"A Menk","year":"2018","unstructured":"Menk, A. v. et al. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J. Exp. Med. 215, 1091\u20131100 (2018).","journal-title":"J. Exp. Med."},{"key":"27613_CR31","doi-asserted-by":"publisher","first-page":"23010","DOI":"10.1074\/jbc.M112.350538","volume":"287","author":"AJ McPherson","year":"2012","unstructured":"McPherson, A. J., Snell, L. M., Mak, T. W. & Watts, T. H. Opposing roles for TRAF1 in the alternative versus classical NF-\u03baB pathway in T cells. J. Biol. Chem. 287, 23010\u201323019 (2012).","journal-title":"J. Biol. Chem."},{"key":"27613_CR32","doi-asserted-by":"crossref","unstructured":"Philipson, B. I. et al. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling. Sci. Signal. 13, eaay8248 (2020).","DOI":"10.1126\/scisignal.aay8248"},{"key":"27613_CR33","doi-asserted-by":"crossref","unstructured":"Lee, D. Y. et al. 4-1BB Signaling Activates the T Cell Factor 1 Effector\/\u03b2-Catenin Pathway with Delayed Kinetics via ERK Signaling and Delayed PI3K\/AKT Activation to Promote the Proliferation of CD8+ T Cells. PLoS ONE 8, e69677 (2013).","DOI":"10.1371\/journal.pone.0069677"},{"key":"27613_CR34","doi-asserted-by":"crossref","unstructured":"Hinterberger, M. et al. Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory. J. Imm.Therapy of Cancer 9, e69677 (2021).","DOI":"10.1136\/jitc-2020-001586"},{"key":"27613_CR35","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1126\/science.283.5402.649","volume":"283","author":"ML Dustin","year":"1999","unstructured":"Dustin, M. L. & Shaw, A. S. Costimulation: Building an immunological synapse. Science 283, 649\u2013650 (1999).","journal-title":"Science"},{"key":"27613_CR36","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.4049\/jimmunol.174.4.1898","volume":"174","author":"K-O Nam","year":"2005","unstructured":"Nam, K.-O. et al. Cross-Linking of 4-1BB Activates TCR-Signaling Pathways in CD8 + T Lymphocytes. J. Immunol. 174, 1898\u20131905 (2005).","journal-title":"J. Immunol."},{"key":"27613_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12026-011-8216-z","volume":"50","author":"J Cheng","year":"2011","unstructured":"Cheng, J., Montecalvo, A. & Kane, L. P. Regulation of NF-\u03baB induction by TCR\/CD28. Immunologic Res. 50, 113\u2013117 (2011).","journal-title":"Immunologic Res."},{"key":"27613_CR38","doi-asserted-by":"crossref","unstructured":"Zapata, J. M. et al. CD137 (4-1BB) signalosome: Complexity is a matter of TRAFs. Front. Immunol. 9, 2618 (2018).","DOI":"10.3389\/fimmu.2018.02618"},{"key":"27613_CR39","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.immuni.2008.08.011","volume":"29","author":"T Yokosuka","year":"2008","unstructured":"Yokosuka, T. et al. Spatiotemporal Regulation of T Cell Costimulation by TCR-CD28 Microclusters and Protein Kinase C \u03b8 Translocation. Immunity 29, 589\u2013601 (2008).","journal-title":"Immunity"},{"key":"27613_CR40","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nri1148","volume":"3","author":"M Croft","year":"2003","unstructured":"Croft, M. Co-stimulatory members of the TNFR family: Keys to effective T-cell immunity? Nat. Rev. Immunol. 3, 609\u2013620 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"27613_CR41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1158\/2326-6066.CIR-17-0249","volume":"6","author":"BL Horton","year":"2018","unstructured":"Horton, B. L., Williams, J. B., Cabanov, A., Spranger, S. & Gajewski, T. F. Intratumoral CD8+ T-cell apoptosis is a major component of T-cell dysfunction and impedes antitumor immunity. Cancer Immunol. Res. 6, 14\u201324 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"27613_CR42","doi-asserted-by":"crossref","unstructured":"Otano, I. et al. Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death. Theranostics 10, 4481\u20134489 (2020).","DOI":"10.7150\/thno.41646"},{"key":"27613_CR43","doi-asserted-by":"crossref","unstructured":"Hinterberger, M. et al. P04.02 A novel cancer immunotherapy combines rMVA-CD40L with tumor targeting antibodies. J. Imm.Therapy. Cancer 8, 5041 (2020).","DOI":"10.1136\/jitc-2020-ITOC7.71"},{"key":"27613_CR44","doi-asserted-by":"crossref","unstructured":"McLane, L. M. et al. Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells. Cell Rep. 35, 109120 (2021).","DOI":"10.1016\/j.celrep.2021.109120"},{"key":"27613_CR45","doi-asserted-by":"crossref","unstructured":"Quintana, A. et al. T cell activation requires mitochondrial translocation to the immunological synapse. Proc. Natl. Acad. Sci. USA. 104, 14418\u201314423 (2007).","DOI":"10.1073\/pnas.0703126104"},{"key":"27613_CR46","doi-asserted-by":"crossref","unstructured":"Melero, I. et al. First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours. in ESMO Virtual Congress S645\u2013S671 (Annals of Oncology, 2020).","DOI":"10.1016\/j.annonc.2020.08.1145"},{"key":"27613_CR47","unstructured":"Velloso, M. J. G. et al. Tumor targeting and tissue biodistribution of RO7122290, a novel FAP-targeted 4-1BB (CD137) agonist, in patients with advanced solid tumors, using [89Zr]-RO7122290 as a PET tracer. In SITC (Journal for ImmunoTherapy of Cancer (JITC), 2020)."},{"key":"27613_CR48","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1038\/nprot.2014.169","volume":"9","author":"AF Labrijn","year":"2014","unstructured":"Labrijn, A. F. et al. Controlled Fab-arm exchange for the generation of stable bispecific IgG1. Nat. Protoc. 9, 2450\u20132463 (2014).","journal-title":"Nat. Protoc."},{"key":"27613_CR49","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1093\/nar\/gng015","volume":"31","author":"RA Irizarry","year":"2003","unstructured":"Irizarry, R. A. et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, e15 (2003).","journal-title":"Nucleic Acids Res."},{"key":"27613_CR50","unstructured":"Gentleman, R. C. et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004)."},{"key":"27613_CR51","doi-asserted-by":"crossref","unstructured":"Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. App. Genet. Mol. Biol. 3, 1027 (2004).","DOI":"10.2202\/1544-6115.1027"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27613-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27613-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27613-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T15:36:32Z","timestamp":1674056192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27613-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["27613"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-27613-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,15]]},"assertion":[{"value":"13 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.M. reports advisory roles with Roche-Genentech, Bristol-Myers Squibb, CYTOMX, Incyte, MedImmune, Tusk, F-Star, Genmab, Molecular Partners, Alligator, Bioncotech, MSD, Merck Serono, Boehringer Ingelheim, Astra Zeneca, Numab, Catalym, and Bayer, and research funding from Roche, BMS, Alligator, and Bioncotech. P.B. reports advisory roles with Tusk and Moderna, research funding from Sanofi, and Bavarian Nordic and speaker honoraria from BMS, MSD, Novartis and AstraZeneca. J.M-E. is a full-time employee of Bavarian Nordic. P.E. and S.F. are employees at Alligator and G.H.H. is an employee at Aptevo. The rest of the authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7296"}}